Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 3.8% in the morning session after the U.S. Food and Drug Administration (FDA) granted full approval for its Spikevax COVID-19 vaccine ...

The Food and Drug Administration on Thursday granted full approval for Moderna’s COVID-19 vaccine Spikevax in children aged 6 months through 11 years who are at an increased risk for COVID disease.

Moderna’s Covid vaccine for children has been given full FDA approval, making it the first such shot for kids in the U.S. that will no longer be administered under an emergency use authorization.

The U.S. Food and Drug Administration has granted full approval for Moderna's COVID-19 vaccine, Spikevax, in children aged 6 months through 11 years who are at an increased risk of the disease ...

The U.S. Food and Drug Administration has granted full approval for Moderna's MRNA.O COVID-19 vaccine, Spikevax, in children aged 6 months through 11 years who are at an increased risk of the ...

The FDA granted full approval to Moderna's COVID-19 vaccine (Spikevax) for kids ages 6 months through 11 years who are at increased risk of severe disease, the company announced.

The latest international Moderna Inc news and views from Reuters - one of the world's largest news agencies ...

↘️ Sunrun (RUN), Enphase Energy (ENPH), First Solar (FSLR): Solar stocks fell Tuesday after the White House said it would enforce the halt to clean-electricity tax credits faster than expected.

Biotech Moderna, Inc. and OriCiro Genomics K.K. have announced they have entered into a definitive agreement for Moderna to acquire OriCiro at a cost of $85 million.

The S&P 500 fell 0.1% on Tuesday, July 8, 2025, after President Trump extended the deadline for "reciprocal" tariffs and discussed a 50% levy on imported copper.

Moderna has said it will open a new R&D and manufacturing facility in the UK which could lead to improved access by NHS patients to mRNA-based vaccines and drug treatments.